1626387-80-1 AZD 3759 CAS NO.1626387-80-1
- FOB Price: USD: 480.00-480.00 /Metric Ton Get Latest Price
- Min.Order: 1 Kilogram
- Payment Terms: L/C,T/T
- Available Specifications:
A(10-150)Metric Ton
- Product Details
Keywords
- AZD3759
- 1626387-80-1 AZD 3759
- 1626387-80-1 AZD 3759
Quick Details
- ProName: 1626387-80-1 AZD 3759
- CasNo: 1626387-80-1
- Molecular Formula: C22H23ClFN5O3
- Appearance: Powder
- Application: Organic Chemicals
- DeliveryTime: according to client's demand quantity
- PackAge: as requested
- Port: SHANGHAI
- ProductionCapacity: 100 Metric Ton/Year
- Purity: 99%
- Storage: room temperature
- Transportation: by Sea
- LimitNum: 1 Kilogram
- Heavy metal: 0.01
- Grade: Industrial Grade,Pharma Grade
- Transportation: LCL
Superiority
Product Name: AZD 3759
Synonyms: AZD 3759;AZD3759;AZD-3759;(2R)-2,4-Dimethyl-1-piperazinecarboxylic acid 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl ester;HY-18750;azd3579;4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl 1-piperazinecarboxylic acid 2,4-dimethyl ester;4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl (2R)-2,4-dimethylpiperazine-1-carboxylate
CAS: 1626387-80-1
MF: C22H23ClFN5O3
MW: 459.91
EINECS: 1592732-453-0
Product Categories: API
Mol File: 1626387-80-1.mol
AZD 3759 Chemical Properties
Boiling point 571.4±50.0 °C(Predicted)
density 1.358±0.06 g/cm3(Predicted)
pka 6.71±0.40(Predicted)
AZD 3759 Usage And Synthesis
Selective EGFR inhibitor
AZD3759 is a selective EGFR inhibitor that can fully penetrate the blood-brain barrier (BBB), with equal free concentrations in the blood, cerebrospinal fluid, and brain tissue. Treatment with AZD3759 causes tumor regression in subcutaneous xenograft, leptomeningeal metastasis (LM), and brain metastasis (BM) lung cancer models and prevents the development of BM in nude mice.
Description AZD3759 is an EGFP inhibitor (Epidermal growth factor receptor tyrosine kinase inhibitor) with blood brain barrier (BBB) penetration. It has the potential for the treatment of non-small cell lung cancer (NSCLC), with brain metastases (BM) and leptomengingeal metastases (LM) since this type of cancer often contain a lot of activating mutations of the epidermal growth factor receptor (EGFR). It has excellent capability of penetrating the blood brain barrier to reach the central nervous system.
References Zeng, Qingbei, et al. "Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)." Journal of Medicinal Chemistry 58.20(2015):8200.
Yang, Zhenfan, et al. "Abstract LB-217: Antitumor activities of AZD3759, a novel EGFR inhibitor with excellent penetration across central nervous system (CNS), in preclinical animal models." Cancer Research 76.14 Supplement(2016):LB-217-LB-217.
Xiong, S., et al. "Determination of AZD3759 in rat plasma and brain tissue by LC-MS/MS and its application in pharmacokinetic and brain distribution studies." Journal of Pharmaceutical & Biomedical Analysis140(2017):362-366.
Details
Product Name: AZD 3759
Synonyms: AZD 3759;AZD3759;AZD-3759;(2R)-2,4-Dimethyl-1-piperazinecarboxylic acid 4-[(3-chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl ester;HY-18750;azd3579;4-[(3-Chloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl 1-piperazinecarboxylic acid 2,4-dimethyl ester;4-((3-chloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl (2R)-2,4-dimethylpiperazine-1-carboxylate
CAS: 1626387-80-1
MF: C22H23ClFN5O3
MW: 459.91
EINECS: 1592732-453-0
Product Categories: API
Mol File: 1626387-80-1.mol
AZD 3759 Chemical Properties
Boiling point 571.4±50.0 °C(Predicted)
density 1.358±0.06 g/cm3(Predicted)
pka 6.71±0.40(Predicted)
AZD 3759 Usage And Synthesis
Selective EGFR inhibitor
AZD3759 is a selective EGFR inhibitor that can fully penetrate the blood-brain barrier (BBB), with equal free concentrations in the blood, cerebrospinal fluid, and brain tissue. Treatment with AZD3759 causes tumor regression in subcutaneous xenograft, leptomeningeal metastasis (LM), and brain metastasis (BM) lung cancer models and prevents the development of BM in nude mice.
Description AZD3759 is an EGFP inhibitor (Epidermal growth factor receptor tyrosine kinase inhibitor) with blood brain barrier (BBB) penetration. It has the potential for the treatment of non-small cell lung cancer (NSCLC), with brain metastases (BM) and leptomengingeal metastases (LM) since this type of cancer often contain a lot of activating mutations of the epidermal growth factor receptor (EGFR). It has excellent capability of penetrating the blood brain barrier to reach the central nervous system.
References Zeng, Qingbei, et al. "Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI)." Journal of Medicinal Chemistry 58.20(2015):8200.
Yang, Zhenfan, et al. "Abstract LB-217: Antitumor activities of AZD3759, a novel EGFR inhibitor with excellent penetration across central nervous system (CNS), in preclinical animal models." Cancer Research 76.14 Supplement(2016):LB-217-LB-217.
Xiong, S., et al. "Determination of AZD3759 in rat plasma and brain tissue by LC-MS/MS and its application in pharmacokinetic and brain distribution studies." Journal of Pharmaceutical & Biomedical Analysis140(2017):362-366.